Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ContraVir Hopes To Establish Backbone For Hepatitis B Combo Therapy

Executive Summary

Two deals have resulted in the formerly shingles-focused biotech beginning to build an HBV pipeline and look ahead to therapeutic advances similar to those seen in HIV and hepatitis C. But the New Jersey biotech will be competing with some deep-pocketed competitors in the space.

Advertisement

Related Content

Hep B Cure May Lie In Reducing Surface Antigen
ContraVir's James Sapirstein Interviewed On Future Of Combination Therapy In HBV
Start-Up Quarterly Statistics, Q2 2016
ContraVir Strikes Deal With Rival Early Stage Hep B Drug Developer
J&J Looks To Get Ahead In Hep B With Combination Strategy
Busy Days For Hep B Drug Development
ContraVir appoints new CMO
Bristol’s Virology Focus Turning To Hepatitis B? An Interview With Doug Manion

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC096933

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel